European Health & Life Sciences Symposium 2026

Emmanuelle Trombe is the co-head of the Firm’s Life Sciences industry practice. She represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. As well as co-heading the Firm’s Life Sciences Group, Emmanuelle serves as an elected member of the Firm’s Management Committee.

Emmanuelle is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is highly recommended for her experience in the pharmaceutical, healthcare, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded. She has been distinguished as the Lawyer of the Year in Life Sciences for 2024.

Anne-France Moreau has over a decade of experience counselling clients on corporate and general commercial law, with a particular focus on pharmaceutical, medical device, health care and cosmetics industries. Anne-France assists French and non-French groups in the preparation and negotiation of collaborations, licenses and distribution agreements. She has experience on a number of merger, acquisition and private equity transactions, including divestitures, financing rounds and joint ventures for French and non-French corporations. Further, Anne-France regularly handles digital health matters as well as regulatory issues.

Anne-France worked in a legal department of a French major leading pharmaceutical company, where she gained experience in pharmaceutical operations.

Anthony Paronneau focuses his practice on a broad range of corporate and transactional matters, with a particular focus on the pharmaceutical, medical device, biotech, and healthcare sectors.

He has extensive experience representing life sciences companies, private equity funds, and venture capital firms in complex M&A and private equity transactions, including acquisitions, venture financings, joint ventures, and divestitures.

Anthony regularly advises emerging growth companies and VC investors on the structuring and negotiation of early- and late-stage funding rounds, and has acted on numerous high-profile cross-border and domestic transactions involving leading innovators in the healthtech and biotech spaces.

In addition, he counsels life sciences clients on strategic partnerships, collaborations, licensing agreements, and distribution arrangements, supporting their growth and commercialization strategies across all stages of development.